BDNF AND ALOX12 DURING ANTIDEPRESSANT TREATMENT IN MAJOR DEPRESSION: A LONGITUDINAL STUDY

Authors

  • V. T. IACOB Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • Ioana-Sorana CARTAS Clinical Hospital of Pneumology Iasi, Romania
  • T. VOLOSENIUC Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • D. C. OPREA Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • T. FLOREA Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania
  • V. OPREA Nicolae Testemitanu State University of Medicine and Pharmacy Chisinau, Moldova
  • D. TURLIUC Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

DOI:

https://doi.org/10.22551/MSJ.2026.02.07

Abstract

This study investigated the longitudinal dynamics of brain-derived neurotrophic factor (BDNF) and arachidonate 12-lipoxygenase (ALOX12) during antidepressant treatment in patients with major depression. Materials and methods: Twenty-six patients were assessed at baseline, 4 weeks, and 8 weeks. Depressive and anxiety symptoms were measured using HAM-D and HAM-A, and plasma BDNF and ALOX12 levels were quantified using ELISA. Results: HAM-D decreased from 31.0 to 23.0 and HAM-A from 28.0 to 18.0. BDNF increased from 0.87 to 5.33, while ALOX12 decreased from 1.39 to 0.22 (p<0.001), with the largest change between weeks 4 and 8; ALOX12 at 8 weeks correlated inversely with HAM-D (r = −0.416; adjusted r = −0.515). Conclusions: BDNF and ALOX12 showed distinct temporal patterns. BDNF increase and ALOX12 reduction occurred without significant associations between their changes.

Author Biographies

  • V. T. IACOB, Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

    Socola Institute of Psychiatry Iasi, Romania

  • D. C. OPREA, Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

    Socola Institute of Psychiatry Iasi, Romania

  • D. TURLIUC, Grigore T. Popa University of Medicine and Pharmacy Iasi, Romania

    Socola Institute of Psychiatry Iasi, Romania

References

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358(1): 55-68.

2. Rush AJ. The varied clinical presentations of major depressive disorder. J Clin Psychiatry 2007; 68 (Suppl 8): 4-10.

3. Price JL, Drevets WC. Neurocircuitry of mood disorders. Neuropsychopharmacology 2010; 35(1): 192-216.

4. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338(6103): 68-72.

5. Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron 2019; 102(1): 75-90.

6. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(3): 676-692.

7. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-457.

8. Black CN, Bot M, Scheffer PG, Cuijpers P, Penninx BW. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuro-endocrinology 2015; 51: 164-175.

9. Kennis M, Gerritsen L, van Dalen M, Williams A, Cuijpers P, Bockting C. Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry 2020; 25(2): 321-338.

10. Malik S, Singh R, Arora G, Dangol A, Goyal S. Biomarkers of Major Depressive Disorder: Knowing is Half the Battle. Clin Psychopharmacol Neurosci 2021; 19(1): 12-25.

11. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165(3): 342-351.

12. Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 2013; 11: 129.

13. Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010; 70(5): 289-297.

14. Notaras M, van den Buuse M. Brain-Derived Neurotrophic Factor (BDNF): Novel Insights into Regulation and Genetic Variation. Neuroscientist. 2019; 25(5): 434-454.

15. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54(7): 597-606.

16. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64(6): 527-532.

17. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentra-tions as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry 2014; 19(7): 791-800.

18. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a bi-omarker for successful treatment of mood disorders: a systematic and quantitative meta-analysis. J Affect Disord 2015; 174: 432-440.

19. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37(12): 1553-1561.

20. Bazinet RP, Layé S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 2014; 15(12): 771-785.

21. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 2006; 52(2): 201-243.

22. Kuhn H, Banthiya S, van Leyen K. Mammalian lipoxygenases and their biological relevance. Biochim Biophys Acta 2015; 1851(4): 308-330.

23. Yoshimoto T, Takahashi Y. Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat 2002; 68-69: 245-262.

24. Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione deple-tion. Neuron 1997; 19(2): 453-463.

25. van Leyen K, Kim HY, Lee SR, Jin G, Arai K, Lo EH. Baicalein and 12/15-lipoxygenase in the ischem-ic brain. Stroke 2006; 37(12): 3014-3018.

26. Fridman C, Ojopi EP, Gregório SP, et al. Association of a new polymorphism in ALOX12 gene with bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2003; 253(1): 40-43.

27. Miller MW, Wolf EJ, Sadeh N, et al. A novel locus in the oxidative stress-related gene ALOX12 moderates the association between PTSD and thickness of the prefrontal cortex. Psychoneuroendocrinology 2015; 62: 359-365.

28. Akiyama S, Nagai H, Oike S, et al. Chronic social defeat stress increases the amounts of 12-lipoxygenase lipid metabolites in the nucleus accumbens of stress-resilient mice. Sci Rep 2022; 12(1): 11385.

29. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16(1): 22-34.

30. Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and thera-peutic implications. Neuroscience 2013; 246: 199-229.

31. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci 2014; 8: 430.

32. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogene-sis. Brain Behav Immun 2011; 25(2): 181-213.

33. Li K, Wang K, Xu SX, et al. Investigating Neuroplasticity Changes Reflected by BDNF Levels in Astrocyte-Derived Extracellular Vesicles in Patients with Depression. Int J Nanomedicine 2024; 19: 8971-8985.

34. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibi-tor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 2006; 63(11): 1217-1223.

35. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163(11): 1905-1917.

36. Harmer CJ, Goodwin GM, Cowen PJ. Why do antidepressants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 2009; 195(2): 102-108.

37. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature 2014; 510(7503): 92-101.

38. Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28(2): 335-341.

39. Fried EI, Nesse RM. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Med 2015; 13: 72.

Additional Files

Published

2026-06-01

Issue

Vol. 130 No. 2 (2026): The Medical-Surgical Journal

Section

INTERNAL MEDICINE - PEDIATRICS

License

Copyright (c) 2026 The Medical-Surgical Journal

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form